Chinese researchers proposed and reported preclinical work on a circular RNA (circRNA) encoding human relaxin‑2 (cRLN2) as a protein‑replacement strategy for liver fibrosis. circRNAs offer increased stability and lower innate immunogenicity versus linear mRNA, and the team demonstrated therapeutic effects in liver disease models consistent with relaxin biology: reduced fibrosis markers and improved tissue metrics. The approach positions circRNA as an alternative modality for durable protein expression in chronic organ disease. Translational steps include scaled manufacturing, immune profiling, and rigorous toxicology to support clinical entry.